Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan.

Growth hormone (GH) replacement therapy for growth hormone deficiency (GHD) in children and adults has for over 25 years, until recently, been administered as daily injections. This daily treatment regimen often incurs a burden to patients and caregivers, leading to high rates of non-adherence and, consequently, decreased treatment efficacy outcomes. To address this shortcoming, long-acting growth hormones (LAGHs) have been developed with the aim of reducing the burden of daily injections, thereby potentially improving treatment adherence and outcomes. Somapacitan (Sogroya

Informations de copyright

© 2024 Miller et al.

Déclaration de conflit d'intérêts

B.S.M.: Consulted for Ascendis Pharma, BioMarin, Bristol Myers Squibb, EMD Serono, Endo Pharmaceuticals, Eton Pharmaceuticals, GenSci, Novo Nordisk, Orchard Therapeutics, Pfizer, Provention Bio, and Tolmar; and received research support from Alexion, AbbVie, Ascendis Pharma, Aeterna Zentaris, Amgen, Amicus, Foresee Pharmaceuticals, Lumos Pharma, Lysogene, Novo Nordisk, OPKO Health, Pfizer, Prevail Therapeutics, and Sangamo Therapeutics. J.B.: Received honoraria for presentations at meetings sponsored by Novo Nordisk, Sandoz, and Ipsen; received sponsorship to attend scientific meetings from Novo Nordisk; and received payment for membership of the Publication Steering Committee of the International Outcomes Study, sponsored by Novo Nordisk. R.H: Advisory board member and lecturer for Novo Nordisk, Pfizer, Lumos Pharma, JCR, and Sandoz. A.L.: Consulted for/received research funding/honoraria from Novo Nordisk, Merck Serono, Alexion, AstraZeneca Rare Disease, and Pfizer Inc; and received honoraria from Ipsen and Sandoz. K.C.J.Y.: Received research grants to Barrow Neurological Institute from Crinetics, Ascendis, Corcept, Amryt, and Sparrow; served as an occasional advisory board member for Novo Nordisk, Ascendis, Ipsen, Amryt, Crinetics, Recordati, Neurocrine, and Xeris; lecture fees from Pfizer; and served as occasional speaker for Recordati and Novo Nordisk.